Related Experiment Video
Updated: Jul 8, 2025
12:28
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
17.4K
Cognitively defined Alzheimer's dementia subgroups have distinct atrophy patterns
Paul K Crane1, Colin Groot2,3, Rik Ossenkoppele2,3
1Department of Medicine, University of Washington, Seattle, Washington, USA.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 14, 2023
Summary
Structural MRI scans reveal distinct brain atrophy patterns in Alzheimer's disease (AD) subgroups. These imaging findings correlate with specific cognitive impairments, aiding in subgroup identification.
Area of Science:
- Neuroimaging
- Neurology
- Alzheimer's Disease Research
Background:
- Alzheimer's disease (AD) heterogeneity presents diagnostic challenges.
- Understanding structural magnetic resonance imaging (MRI) variations across AD cognitive subtypes is crucial.
Purpose of the Study:
- To identify specific MRI characteristics in AD subgroups based on cognitive impairments.
- To compare cognitively defined subgroups with imaging-defined subgroups.
Main Methods:
- Utilized data from the Alzheimer's Disease Neuroimaging Initiative (ADNI).
- Included 584 individuals with AD (461 amyloid-positive) and 118 amyloid-negative controls.
- Employed voxel-based morphometry to assess gray matter volume (GMV) differences.
Main Results:
- AD-Memory subgroup showed medial temporal lobe atrophy.
- AD-Language subgroup exhibited left hemisphere GMV reduction and significant asymmetry.
- AD-Executive and AD-Visuospatial subgroups displayed anterior and posterior GMV reductions, respectively.
- Cognitively defined AD-Memory subgroup aligned with an imaging-defined limbic predominant group.
Conclusions:
- Distinct MRI patterns correlate with specific cognitive deficits in Alzheimer's disease.
- These findings support the differentiation of AD subtypes based on neuroimaging and cognitive profiles.
Keywords:
Alzheimer's disease dementiaasymmetryatrophycognitive heterogeneityneurodegenerationsubgroupsMore Related Videos
Related Concept Videos
01:26Alzheimer's Disease: Overview
492
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
492
01:30Dementia
115
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
115
01:22Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195